

## TABLE OF CONTENTS

Contents	Page No.
<b>Abstract</b>	<b>i-vi</b>
<b>Declaration</b>	
<b>Certificate</b>	
<b>Acknowledgments</b>	<b>vii-viii</b>
<b>Table of Contents</b>	<b>ix-xv</b>
<b>List of Tables</b>	<b>xvi-xvii</b>
<b>List of Figures</b>	<b>xviii-xxx</b>
<b>Abbreviations</b>	<b>xxxi-xxxiv</b>

### CHAPTER-I

<b>INTRODUCTION</b>	<b>1-30</b>
1.1 neurodegenerative diseases- a concern for millions of people worldwide	1-4
1.1.1 Types of neurodegenerative diseases and current treatments	5-7
1.1.1.1 Alzheimer's disease	5
1.1.1.2 Parkinson's disease	5
1.1.1.3 Amyotrophic lateral sclerosis	6
1.1.1.4 Huntington's disease	7
1.1.2 Oxidative stress and neurodegenerative disorders	8-9
1.1.2.1. Neuroinflammation	8
1.1.2.2. Mitochondrial dysfunction	8
1.1.2.3. Release of Cytochrome c	9
1.1.2.4. Apoptosis	9
1.1.3 Challenges associated with current therapy	10
1.2 Neurotrophins: Role in neurological disorders and prospects	11-15
1.2.1. Neurotrophins and their receptors	11
1.2.2. Snake venom neurotrophins	12
1.2.3. Neurotrophins signaling pathways	13
1.2.4. Neurotrophins as therapeutics in NDs	14
1.2.5 Limitations of neurotrophins as a therapeutic in neurological diseases	15
1.3 Peptidomimetics and small molecules therapeutics	15
1.3.1 Neurotrophin's mimetics role in neurological diseases	15
1.4 Model organism for neurobiological studies	16-17
1.4.1. Rat pheochromocytoma (PC-12) cell as an <i>in vitro</i> model	16
1.4.2. Caenorhabditis elegans ( <i>C. elegans</i> ) as <i>in vivo</i> model	16

1.4.3. Micro-RNAs	17
1.5 Gap in the study	18
1.6 Objectives of this study	18
Bibliography	19-30

---

<b>Contents</b>	<b>TABLE OF CONTENTS</b>	<b>Page no.</b>
-----------------	--------------------------	-----------------

---

<b>CHAPTER II</b>	
<b>REVIEW OF LITERATURE</b>	<b>31-55</b>
2.1 Therapeutic role of conventional neurotrophins and neurotrophic factors (NTFs) derived from natural resources for treating neurodegenerative diseases	32-33
2.1.1 BDNF delivery as a therapeutic target for PD and HD	32
2.1.2 NGF delivery as a therapeutic target for AD	33
2.2 The challenges associated with the therapeutic application of conventional neurotrophins in treating NDs	33
2.3 Advantages of neurotrophin mimetic molecules over parent neurotrophins as therapeutics	34
2.4 Trends in the discovery of therapeutic peptide	
2.5 Application of peptidomimetics as drug prototypes to treat NDs	35- 44
2.5.1. Peptide mimetics to NGF and TrkA receptor	36
2.5.2. Peptide mimetics to BDNF and TrkB receptor	36-38
2.5.3. Peptide mimetics to NT-3 and Trk-C receptor	38-40
2.6 Snake venom-derived peptidomimetics as therapeutics to treat neurodegenerative disorders	40 45
Bibliography	46-55

---